In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Told You So....

Executive Summary

Protein Design Labs' announcement that it would discontinue trials of its antibody Zenapax against psoriasis was no surprise to SG Cowen analyst Bill Tanner, who'd reported at the end of February that clinicians involved in testing weren't very enthusiastic about it. Tanner may have been bloodied by criticism that his report was based on data that could not be statistically significant--but he remained unbowed. PDL's news reaffirmed his belief that analysts need to do fundamental research and talk to clinicians, instead of simply believing everything a company says.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts